Skip to main content

Recent News

Israeli study of 1497 fully vaccinated health care workers finds 39 (2.4% Breakthrough COVID infections (Jan-May 2021), most cases were mild or asymptomatic, 19% w/ persistent Sxs (>6 ws); infected had lower neutralizing Abs. https://t.co/deYTVLRQCU

Dr. John Cush @RheumNow (  View Tweet)

Oct 25, 2021
ATOM study - Phase 3 RCT testing abaloparatide (Tymlos) in 228 men with osteoporosis. At 12 mos Tymlos shows signif increase in lumbar BMD of 1.2%. Also increased were hip and femoral neck BMD at 12 months. https://t.co/WC3ygkyMZH

Dr. John Cush @RheumNow (  View Tweet)

Oct 25, 2021
ICYMI: In a real world study of lupus patients, aspirin use lowered risk of preeclampsia, as did hydroxychloroquine. Risk Factors for preeclampsia were high Dz activity 1st trimester(OR 4.55),BMI >30 (6.14),antiphospholipid synd (8.02),hx preeclampsia (9.8)https://t.co/giBamMAPRM https://t.co/NHKxlmEHQj
Dr. John Cush @RheumNow (  View Tweet)
Oct 24, 2021
Rheumatologist Smoke-Enders available for download wherever you get your podcasts. https://t.co/o35tuNgk8R https://t.co/pksojrC5Wb
Dr. John Cush @RheumNow (  View Tweet)
Oct 24, 2021
"Progress is a nice word. But change is its motivator and change has its enemies." - Robert F. Kennedy https://t.co/sIVym3e80c
Dr. John Cush @RheumNow (  View Tweet)
Oct 24, 2021
ICYMI: Nice full read review of IL-23 in Rheumatology - its biology and clinical targeting. IL-23 is a coordinating cytokine in psoriasis, psoriatic arthritis and inflammatory bowel disease. https://t.co/tDWZuV6Tao https://t.co/0p8RGnnE9B
Dr. John Cush @RheumNow (  View Tweet)
Oct 24, 2021
ICYMI: Propensity matched comparison of Tramadol vs Codeine use. Tramadol had a signif. higher risk of all-cause mortality (HR, 2.31), CV events (HR 1.15) & fractures (HR 1.50), but no diff in falls, delirium, constipation, opioid abuse, sleep disorders. https://t.co/nBUe5VV1D3 https://t.co/C3r0Fur4xJ
Dr. John Cush @RheumNow (  View Tweet)
Oct 24, 2021
Congratulations to friend and mentor, Dr. Stan Cohen for receiving this years ACR Gold Medal award - the highest award that the ACR can bestow. Stan was a past ACR President & has been a leading educator and researcher in rheumatology https://t.co/EJQ5tc3dhc

Dr. John Cush @RheumNow (  View Tweet)

Oct 23, 2021
ICYMI:Pregabalin (lyrica) for Fibromyalgia 75 mg bid; may be increased to max dose 450 mg/d.(Reduce for renal dz). Indications: DM neuropathy/pain, post-herpetic neuralgia, partial seizures. Rare AE: Angioedema, low Plts, ^PR interval, rhabdo, gynecomastia https://t.co/r4cH7n9qWD

Dr. John Cush @RheumNow (  View Tweet)

Oct 23, 2021
ICYMI: B-cell depletion therapy with obinutuzumab, a type II anti-CD20 monoclonal antibody, in lupus nephritis patients was shown to be effective in in combination with standard lupus therapies. https://t.co/pMXWmuJw5Y https://t.co/RhWdVir6yB
Dr. John Cush @RheumNow (  View Tweet)
Oct 23, 2021

Increased Preterm Birth Risk in Psoriatic Arthritis Pregnancies

Oct 22, 2021

Pregnancy outcomes may be affected by psoriatic arthritis or antirheumatic treatment; registry cohort study shows that preterm birth and cesarean delivery were mostly increased by antirheumatic treatment, especially biologics.

Read Article
ICYMI: FDA Approves Cyltezo, the 1st INTERCHANGEABLE Biosimilar to Humira - interchangeable means this biosimilar may be substituted for the Humira without the prescriber notice (by pharmacy)in same way generics are substituted for brand name drugs https://t.co/xvinL7UKNU https://t.co/8y5asZ7NWq
Dr. John Cush @RheumNow (  View Tweet)
Oct 22, 2021
New podcast up! Rheumatologist Smoke-Enders https://t.co/o35tuNgk8R https://t.co/iEqVoggl32
Dr. John Cush @RheumNow (  View Tweet)
Oct 22, 2021
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Insights Read the full article on #RheumNow https://t.co/294Au0Q1c3 https://t.co/c1X2T5G4jW
Dr. John Cush @RheumNow (  View Tweet)
Oct 22, 2021
RECOVERY study of hospitalized COVID-19 pts compared colchicine to PBO (+usual care). Colchicine had no effect on 28d mortality (21% vs 21%), time to D/C(10 d vs 10d), LIve D/C (70 vs 70%), mechanical vent or death (25 vs 25%) https://t.co/dYZglKzwxC

Dr. John Cush @RheumNow (  View Tweet)

Oct 22, 2021
Nice full read review of IL-23 in Rheumatology - its biology and clinical targeting. IL-23 is a coordinating cytokine in psoriasis, psoriatic arthritis and inflammatory bowel disease. https://t.co/tDWZuV6Tao

Dr. John Cush @RheumNow (  View Tweet)

Oct 22, 2021
Propensity matched comparison of Tramadol vs Codeine use. Tramadol had a signif. higher risk of all-cause mortality (HR, 2.31), CV events (HR 1.15) & fractures (HR 1.50), but no diff in falls, delirium, constipation, opioid abuse, sleep disorders. https://t.co/nBUe5VV1D3 https://t.co/DHzrXQ2nr1
Dr. John Cush @RheumNow (  View Tweet)
Oct 22, 2021

Smoking Impairs Methotrexate Efficacy

Oct 21, 2021

The Journal of Rheumatology reports that current smoking significantly reduces the clinical efficacy of methotrexate (MTX)-based therapy, as studied in an early rheumatoid arthritis (RA) cohort.

Using data from the CAMERA-II trial (which included early RA patients) they studied MTX treated patients who were randomized to concomitant prednisone (MTX + pred) or placebo (MTX + PBO) for 24 months.

Read Article
September’s most popular read: 11 Drugs That Cause Arthritis https://t.co/GsV0Qj9ENr https://t.co/DNI9bqgKym
Dr. John Cush @RheumNow (  View Tweet)
Oct 21, 2021
In PsA trials, over time the (ACR20) placebo response has increased (15% every 5 yrs)but was not associated with the active treatment effect size. 42 RCTs, the pooled placebo response was 20.3%; pooled treatment effect vs placebo was 27% https://t.co/b9LRpvcTir

Dr. John Cush @RheumNow (  View Tweet)

Oct 21, 2021
×